



# Influenza Recommendations Update and Work Group Considerations

**Lisa Grohskopf, MD, MPH**

October 25, 2017

# Acknowledgments

## Influenza Division

Noreen Alabi  
Lenee Blanton  
Lynnette Brammer  
Joe Bresee  
Alicia Budd  
Jessie Chung  
Jill Ferdinands  
Brendan Flannery  
Alicia Fry  
Dan Jernigan  
Jackie Katz  
Krista Kniss  
Natalie Kramer  
Desiree Mustaquim  
Sonja Olsen  
Leslie Sokolow  
Calli Taylor  
Jerry Tokars  
Tim Uyeki

## Immunization Safety Office

Karen Broder  
Frank Destefano  
Penina Haber  
Tom Shimabukuro

## Immunization Services Division

Carla Black  
Carolyn Bridges  
Sam Graitcer  
Andrew Kroger  
Amy Parker Fiebelkorn  
Tammy Santibanez  
Jeanne Santoli  
Jim Singleton  
Yusheng Zhai

# 2017-18 ACIP Influenza Recommendation Updates

- Published in MMWR August 25, 2017
- Since publication, one influenza vaccine licensure change:
  - Afluria Quadrivalent (IIV4, Seqirus), previously licensed for ages  $\geq 18$  years, now licensed for ages  $\geq 5$  years (same age indication as trivalent formulation of Afluria)

# Work Group Discussion— Flumist Quadrivalent (LAIV4)

- Discussion topics included design/analysis of the non-U.S. observational studies; shedding as a correlate of protection
- No policy change proposed for this meeting
- Anticipated for discussion at February 2018 ACIP meeting
  - Results of U.S. pediatric shedding study
  - Analysis of combined LAIV effectiveness data from U.S. observational studies
  - Systematic review of post-pandemic LAIV effectiveness

# Work Group Discussion— VSD Study of Spontaneous Abortion Following Influenza Vaccine

- Discussion included
  - Early median gestational age of SAB events
  - Biologic plausibility
  - Decrease in magnitude of association from 2010-11 to 2011-12
- Previous studies (including one of similar design to the currently study, conducted prior to the 2009 pandemic) have not noted an association
- No policy change proposed for this meeting
  - Current language states that “Influenza vaccine can be given at any time during pregnancy, before and during the influenza season”
  - Age-appropriate inactivated or recombinant vaccine recommended
- Results of follow-up study anticipated in 2018 or 2019

For more information, contact CDC  
1-800-CDC-INFO (232-4636)  
TTY: 1-888-232-6348 [www.cdc.gov](http://www.cdc.gov)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

